These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 30013569)
1. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond. King LA; Lameris R; de Gruijl TD; van der Vliet HJ Front Immunol; 2018; 9():1519. PubMed ID: 30013569 [TBL] [Abstract][Full Text] [Related]
2. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. Hung JT; Huang JR; Yu AL J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781 [TBL] [Abstract][Full Text] [Related]
3. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Wu L; Gabriel CL; Parekh VV; Van Kaer L Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798 [TBL] [Abstract][Full Text] [Related]
4. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. Araki M; Miyake S; Yamamura T Curr Med Chem; 2008; 15(23):2337-45. PubMed ID: 18855664 [TBL] [Abstract][Full Text] [Related]
5. Roles of NKT cells in cancer immunotherapy. Bae EA; Seo H; Kim IK; Jeon I; Kang CY Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432 [TBL] [Abstract][Full Text] [Related]
8. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990 [TBL] [Abstract][Full Text] [Related]
9. Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses. Zhang L; Donda A Front Immunol; 2017; 8():1417. PubMed ID: 29163493 [TBL] [Abstract][Full Text] [Related]
10. iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. Corgnac S; Perret R; Zhang L; Mach JP; Romero P; Donda A J Immunother Cancer; 2014; 2(1):39. PubMed ID: 25426294 [TBL] [Abstract][Full Text] [Related]
13. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells. Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330 [TBL] [Abstract][Full Text] [Related]
14. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer. Seki T; Liu J; Brutkiewicz RR; Tsuji M Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929 [TBL] [Abstract][Full Text] [Related]
15. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Berkers CR; Ovaa H Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372 [TBL] [Abstract][Full Text] [Related]
17. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells. Yang G; Artiaga BL; Lewis ST; Driver JP Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168 [TBL] [Abstract][Full Text] [Related]
18. Comparison of 6B11 mAb and α-GalCer-loaded CD1d dextramers for detection of iNKT cells by flow cytometry. Lenart M; Gruca A; Mueck A; Rutkowska-Zapała M; Surman M; Szaflarska A; Kobylarz K; Baran J; Siedlar M J Immunol Methods; 2017 Jul; 446():1-6. PubMed ID: 28365328 [TBL] [Abstract][Full Text] [Related]